Estimated event-free survival benefits with dapagliflozin in hf with mildly reduced or preserved ejection fraction
Vaduganathan M, Claggett BL, Jhund P et, al.
J Am Coll Cardiol. 2022;S0735-1097(22)06611-6
Leggi
Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction
Cunningham JW, Vaduganathan M, Claggett BL, et al.
J Am Coll Cardiol. 2022;S0735-1097(22)05673-X.
Leggi
Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure
Lopez PD, Bhatia K, Bohra C, et al.
Am J Cardiol. 2022;S0002-9149(22)00750-0.
Leggi
Lower versus higher glycemic criteria for diagnosis of gestational diabetes
Crowther CA, Samuel D, McCowan LME, et al.
N Engl J Med. 2022;387:587-598.
Leggi
Global mortality of diabetic foot ulcer: a systematic review and meta‐analysis of observational studies
Chen L, Sun S, Gao Y, Ran X
DOM. Pub. online 20 August 2022.
Leggi
Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6
Strain WD, Frenkel O, James MA
Stroke. 2022;53(9):2749-2757.
Leggi
Increased prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes and hypertension: The SWEET international database
Vazeou A, Tittel SR, Kordonouri O, et al.
DOM. Pub. online 18 August 2022.
Leggi
Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
Pitt B, Bhatt DL, Metra M
Eur Heart J. 2022;ehac417.
Leggi